Category: Cancer Treatments

Home / Cancer Treatments

Categories

Can CAR T-Cell manufacturing time be reduced to just one day?

April 2022: Normally, the cell manufacturing procedure for CAR T-cell therapy takes nine to fourteen days; however, researchers at the University of Pennsylvania were able to create functional CAR T c...

CAR T-Cell therapy in solid tumors – A research study

March 2022: Blood vessels are supposed to behave like trees, pouring oxygen into tissues in order for them to flourish and immune cells to clean infections out. The forest, on the other hand, can go a...

CAR T- cell therapy for breast cancer is on the cards

March 2022: According to researchers at the UNC Lineberger Comprehensive Cancer Center, adding a tiny chemical to a treatment process called chimeric antigen receptor-T (CAR-T) cell therapy can boost...

CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma

March 2022: According to Johnson & Johnson, a therapy developed by the company and its China-based partner Legend Biotech Corp to treat a kind of white blood cell cancer has been approved by the...

CAR-T Cell therapy could be made safer and more widely available with a few adjustments

March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment's remarkable effect on tumours comes at the expense of subs...

CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment cost, latest CAR-T clinical trial recruitment

March 2022: CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment price, cost, the latest CAR-T clinical trial recruitment information summary. The concept of boron neu...

Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma

March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, the Food and Drug Administration ...

Abatacept is approved for prophylaxis of acute graft versus host disease

March 2022: Abatacept (Orencia, Bristol-Myers Squibb Company) has been approved by the Food and Drug Administration for the prevention of acute graft versus host disease (aGVHD) in adults and paediat...

Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma

March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), is a safe and effective first...

Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications

March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lympho...

Scan the code